Pacira BioSciences, Inc. Common Stock

PCRXNASDAQUSD
22.37 USD
0.33 (1.46%)🟢LIVE (AS OF 12:57 PM EDT)
🟢Market: OPEN
Open?$22.60
High?$23.04
Low?$22.37
Prev. Close?$22.70
Volume?132.4K
Avg. Volume?878.5K
VWAP?$22.55
Rel. Volume?0.15x
Bid / Ask
Bid?$22.43 × 100
Ask?$22.52 × 100
Spread?$0.09
Midpoint?$22.48
Valuation & Ratios
Market Cap?919.1M
Shares Out?40.5M
Float?40.5M
Float %?94.2%
P/E Ratio?130.67
P/B Ratio?1.33
EPS?$0.17
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.54Strong
Quick Ratio?3.28Strong
Cash Ratio?1.31Strong
Debt/Equity?0.54Moderate
ValuationATTRACTIVELY VALUED
Score
89/100
P/E?
130.7PRICEY
P/B?
1.33CHEAP
P/S?
1.27CHEAP
P/FCF?
6.7CHEAP
EV/EBITDA?
10.3CHEAP
EV/Sales?
1.56CHEAP
Returns & Efficiency
ROE?
1.0%WEAK
ROA?
0.6%WEAK
Cash Flow & Enterprise
FCF?$136.7M
Enterprise Value?$1.1B
Related Companies
Loading...
News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
919.1M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052